Walgreens Boots Alliance (WBA stock) finished the NASDAQ session closed on 06 Mar 2026 at $11.98 on unusually heavy volume of 452,081,061.00 shares. The price sits above the 50-day average $11.66 and 200-day average $10.81, while the company carries a negative EPS of -7.29 and a negative PE of -1.64. We review why WBA was one of the most active names today, connect key financial metrics to the trading spike, and outline near-term price scenarios for investors in the United States market in USD.

WBA stock intraday summary and trading activity

WBA stock closed at $11.98 on NASDAQ with 452,081,061.00 shares traded, versus an average daily volume of 16,940,296.00. That produced a relative volume of 26.69, making Walgreens one of the most active tickers by volume today. The day’s high and low matched at $11.98, reflecting after-hours or snapshot pricing in our feed. The intraday trade pushed WBA well above the 50-day average $11.66 and the 200-day average $10.81, signaling short-term buying interest.

WBA stock valuation and financials

Walgreens Boots Alliance posts a market cap of $10,369,421,068.00, revenue per share TTM 178.73, and book value per share 8.46. Key ratios include PE -1.64, price-to-sales 0.07, and price-to-book 1.44. Net income per share TTM is -7.28, and the company shows heavy leverage with debt-to-equity 4.04 and interest coverage -6.13. These metrics explain mixed investor sentiment and a cautious analyst stance.

WBA stock technicals and momentum

Technical signals today were mixed: Relative Strength Index reads 100.00, ADX 50.00 indicating a strong short-term trend, and ATR 0.16 showing low price range. On balance volume (OBV) reflects the large traded quantity at 452,081,061.00. The stock’s YTD return is 30.36% and one-year return is 32.23%, but long-term performance over three and five years is negative, underlining structural challenges.

Meyka AI grade, analyst split, and WBA forecast

Meyka AI rates WBA with a score out of 100: the platform assigns a Score: 62.52 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 and sector comparison, financial growth, key metrics, and analyst consensus. The street shows a split with 1 Hold and 1 Sell on record, consensus value 2.00. Meyka AI’s forecast model projects $4.08, which compared to the current price $11.98 implies an expected downside of -65.94%. Forecasts are model-based projections and not guarantees.

Drivers, risks and sector context for WBA stock

Short-term drivers include heavy volume, seasonal pharmacy demand, and retail promotions. The Healthcare sector and Medical – Pharmaceuticals industry trends matter for margin recovery and pharmacy reimbursement. Key risks are high leverage, negative EPS, and interest coverage constraints. Opportunities include free cash flow improvement and international operations scaling. We note Walgreens’ next earnings announcement scheduled for 2025-06-25 which could shift sentiment.

Price targets, scenario analysis and WBA trading strategy

Given mixed fundamentals, we present scenario targets: conservative target $8.00, base target $12.00, bullish target $15.00. These reflect possible outcomes around cost controls, pharmacy margins, and asset sales. Traders seeking short-term momentum may watch volume spikes and 50-day average crossovers; longer-term investors should focus on leverage reduction and operating cash flow per share $1.82. Always size positions relative to portfolio risk and liquidity needs.

Final Thoughts

WBA stock closed at $11.98 on NASDAQ on 06 Mar 2026 with an outsized volume of 452,081,061.00 shares, making it one of the most active tickers today. Financials show revenue per share 178.73 but a negative EPS -7.29 and stretched leverage, producing a mixed outlook. Meyka AI rates WBA with a score out of 100 and assigns B / HOLD, balancing sector positives against weak profitability. Meyka AI’s forecast model projects $4.08, implying an approximate -65.94% downside from today’s price; forecasts are model-based and not guarantees. For active traders, today’s volume spike signals short-term attention; for longer-term holders, improvement in interest coverage and operating cash flow per share $1.82 will be key. Monitor the 50-day and 200-day averages, upcoming earnings on 2025-06-25, and any company updates that affect pharmacy margins and debt reduction strategies. We use Meyka AI’s real-time tools to flag moving volumes and valuation shifts as part of our ongoing WBA stock analysis and coverage.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.